Novavax beats quarterly revenue estimates on milestone payment
06/11/2025 12:55
Nov 6 (Reuters) - Novavax NVAX.O beat Wall Street expectations for third-quarter revenue on Thursday, helped by milestone payments tied to its COVID-19 vaccine partnerships. The biotech firm reported total revenue of $70.4 million, compared with analysts' average estimate of $42.13 million, according to data compiled by LSEG. (Reporting by Siddhi Mahatole in Bengaluru) ((siddhi.mahatole@thomsonreuters.com;))
Recent news on Novavax
See all newsNovavax shareholder Shah Capital to step back from activist role
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects
Brief: Sanofi Spokesperson Says Nuvaxovid to Be Available Across U.S. for 2026-27 Respiratory Virus Season
US FDA approves updated COVID vaccines for 2026-27 season
US STOCKS-Wall St rises as yields ease, Moderna lifts healthcare stocks